U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06834451) titled 'Bioequivalence Study of Revolade(R) Eltrombopag 50 Mg' on Jan. 23.
Brief Summary: Bioequivalence Study
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Healthy
Healthy Donors
Intervention:
DRUG: Revolade(R)
Tableta 50 mg Reference
DRUG: Eltrombopag (EPAG)
Tableta 50 mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Centro de Atencion e Investigacion Medica
Information provided by (Responsible Party): Humberto Reynales MD MSc PhD, Centro de Atencion e Investigacion Medica
Published by HT Digital Content Services with permission from Health Daily Digest....